These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 1759540

  • 1. Effects of exogenous growth hormone pretreatment on the pituitary growth hormone response to growth hormone-releasing hormone alone or in combination with pyridostigmine in type I diabetic patients.
    Giustina A, Bossoni S, Bodini C, Cimino A, Pizzocolo G, Schettino M, Wehrenberg WB.
    Acta Endocrinol (Copenh); 1991 Nov; 125(5):510-7. PubMed ID: 1759540
    [Abstract] [Full Text] [Related]

  • 2. Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback.
    Ismail IS, Scanlon MF, Peters JR.
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):149-57. PubMed ID: 8094648
    [Abstract] [Full Text] [Related]

  • 3. Effect of pyridostigmine on the growth hormone response to growth hormone-releasing hormone in lean and obese type II Diabetic patients.
    Giustina A, Bresciani E, Tassi C, Girelli A, Valentini U.
    Metabolism; 1994 Jul; 43(7):893-8. PubMed ID: 8028515
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pyridostigmine enhances even if it does not normalize the growth hormone responses to growth hormone-releasing hormone in patients with Cushing's disease.
    Giustina A, Bossoni S, Bodini C, Ferrari C, Pizzocolo G, Scalvini T, Schettino M, Wehrenberg WB.
    Horm Res; 1991 Jul; 35(3-4):99-103. PubMed ID: 1806475
    [Abstract] [Full Text] [Related]

  • 10. Radiation and neuroregulatory control of growth hormone secretion.
    Ogilvy-Stuart AL, Wallace WH, Shalet SM.
    Clin Endocrinol (Oxf); 1994 Aug; 41(2):163-8. PubMed ID: 7923820
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Different effects of pyridostigmine on growth hormone (GH) response to GH-releasing hormone in endogenous and exogenous hypercortisolemic patients.
    Borges MH, Castro RC, Kater CE, Lengyel AM.
    Braz J Med Biol Res; 1993 Nov; 26(11):1191-200. PubMed ID: 7907904
    [Abstract] [Full Text] [Related]

  • 13. Pyridostigmine fails to increase either spontaneous or GHRH-stimulated GH secretion during day or night in growth hormone-insufficient children.
    Kirk JM, Ross RJ, Trainer PJ, Froud AL, Davies SC, Savage MO, Besser GM.
    Clin Endocrinol (Oxf); 1991 May; 34(5):407-11. PubMed ID: 2060150
    [Abstract] [Full Text] [Related]

  • 14. Impaired growth hormone (GH) response to pyridostigmine in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion.
    Giustina A, Bossoni S, Cimino A, Pizzocolo G, Romanelli G, Wehrenberg WB.
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1486-90. PubMed ID: 2229305
    [Abstract] [Full Text] [Related]

  • 15. Cholinergic modulation of growth hormone responses to growth hormone-releasing hormone in uraemic patients on peritoneal dialysis.
    Díez JJ, Iglesias P, Selgas R, Bajo MA, Aguilera A.
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):587-93. PubMed ID: 11106919
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Growth hormone (GH) response to combined pyridostigmine and GH-releasing hormone administration in patients with Prader-Labhard-Willi syndrome.
    Cappa M, Grossi A, Borrelli P, Ghigo E, Bellone J, Benedetti S, Carta D, Loche S.
    Horm Res; 1993 Nov; 39(1-2):51-5. PubMed ID: 8406340
    [Abstract] [Full Text] [Related]

  • 19. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E, Di Vito L, Ramunni J, Gianotti L, Giordano R, Deghenghi R, Camanni F, Ghigo E.
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.